Tissue Regenerative Materials Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Tissue Regenerative Material is a biomaterial component which facilitates regeneration of lost periodontal hard and soft tissue. One unit refers to one ml of tissue regenerative material.

Tissue Regenerative Materials Pipeline market research report including provides comprehensive information about the Tissue Regenerative Materials pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Which are the key territories in the tissue regenerative materials pipeline market?

The key territories in the tissue regenerative materials pipeline market are the United States, Europe, Japan, New Zealand, Taiwan, and Australia. The United States has the highest number of pipeline products.

Tissue regenerative materials pipeline market, by territories

Tissue regenerative materials pipeline market, by territories

For more territory insights, download a free report sample

Which are the key regulatory paths in the tissue regenerative materials pipeline market?

The key regulatory paths in the tissue regenerative materials pipeline market are 510(k), CE, Ninsho, TGA, and BOPA. 510(k) has the highest number of pipeline products.

Tissue regenerative materials pipeline market, by regulatory paths

Tissue regenerative materials pipeline market, by regulatory paths

For more regulatory path insights, download a free report sample

Which are the key companies in the tissue regenerative materials pipeline market?

The key companies in the tissue regenerative materials pipeline market are Advanced Biotech Products Pvt Ltd, Colorado Therapeutics, LLC, credentis AG, Histocell SL, Indian Institute of Technology Bombay, Maxigen Biotech Inc, and Medtronic Plc.

Market report overview

Key territories United States, Europe, Japan, New Zealand, Taiwan, and Australia
Key regulatory paths 510(k), CE, Ninsho, TGA, and BOPA
Key companies Advanced Biotech Products Pvt Ltd, Colorado Therapeutics, LLC, credentis AG, Histocell SL, Indian Institute of Technology Bombay, Maxigen Biotech Inc, and Medtronic Plc

Scope

  • Extensive coverage of the Tissue Regenerative Materials under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Tissue Regenerative Materials and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Tissue Regenerative Materials under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Advanced Biotech Products Pvt Ltd
Colorado Therapeutics, LLC
credentis AG
Histocell SL
Indian Institute of Technology Bombay
Maxigen Biotech Inc
Medtronic Plc
Nobel Biocare Services AG
Novatissue SAS
Orthocell Ltd
Orthorebirth Co Ltd
Polytechnic University of Catalonia
Straumann Holding AG
SurgaColl Technologies Ltd
SweetBio, Inc.
Tetratherix Pty Ltd
Tigran Technologies AB

Table of Contents

1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 7

2 Introduction 8

2.1 Tissue Regenerative Materials Overview 8

3 Products under Development 9

3.1 Tissue Regenerative Materials – Pipeline Products by Stage of Development 9

3.2 Tissue Regenerative Materials – Pipeline Products by Territory 10

3.3 Tissue Regenerative Materials – Pipeline Products by Regulatory Path 11

3.4 Tissue Regenerative Materials – Pipeline Products by Estimated Approval Date 12

3.5 Tissue Regenerative Materials – Ongoing Clinical Trials 13

4 Tissue Regenerative Materials – Pipeline Products under Development by Companies 14

4.1 Tissue Regenerative Materials Companies – Pipeline Products by Stage of Development 14

4.2 Tissue Regenerative Materials – Pipeline Products by Stage of Development 15

5 Tissue Regenerative Materials Companies and Product Overview 16

5.1 Advanced Biotech Products Pvt Ltd Company Overview 16

5.1.1 Advanced Biotech Products Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 16

5.2 Colorado Therapeutics, LLC Company Overview 19

5.2.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 19

5.3 credentis AG Company Overview 20

5.3.1 credentis AG Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 Histocell SL Company Overview 21

5.4.1 Histocell SL Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Indian Institute of Technology Bombay Company Overview 22

5.5.1 Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 Maxigen Biotech Inc Company Overview 23

5.6.1 Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 23

5.7 Medtronic Plc Company Overview 24

5.7.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 24

5.8 Nobel Biocare Services AG Company Overview 25

5.8.1 Nobel Biocare Services AG Pipeline Products & Ongoing Clinical Trials Overview 25

5.9 Novatissue SAS Company Overview 26

5.9.1 Novatissue SAS Pipeline Products & Ongoing Clinical Trials Overview 26

5.10 Orthocell Ltd Company Overview 27

5.10.1 Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview 27

5.11 Orthorebirth Co Ltd Company Overview 28

5.11.1 Orthorebirth Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

5.12 Polytechnic University of Catalonia Company Overview 29

5.12.1 Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview 29

5.13 Straumann Holding AG Company Overview 30

5.13.1 Straumann Holding AG Pipeline Products & Ongoing Clinical Trials Overview 30

5.14 SurgaColl Technologies Ltd Company Overview 31

5.14.1 SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.15 SweetBio, Inc. Company Overview 32

5.15.1 SweetBio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

5.16 Tetratherix Pty Ltd Company Overview 33

5.16.1 Tetratherix Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

5.17 Tigran Technologies AB Company Overview 36

5.17.1 Tigran Technologies AB Pipeline Products & Ongoing Clinical Trials Overview 36

6 Tissue Regenerative Materials- Recent Developments 37

6.1 May 26, 2022: CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results 37

6.2 Apr 13, 2022: CollPlant To Present at the Aesthetics Innovation Summit 2022 38

6.3 Mar 24, 2022: CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results 39

6.4 Feb 15, 2022: Straumann Group reports revenue exceeding CHF 2 billion 40

6.5 Feb 04, 2022: Straumann Group announces invitation for 2021 full-year financial results webcast 42

6.6 Jan 25, 2022: Medprin Regenerative Medical Technologies Announces on the resignation of the company’s director and board secretary 43

6.7 Jan 07, 2022: Collagen Matrix Names Tony Orsini Chief Operating Officer 43

6.8 Dec 21, 2021: Maipu Medical Announcement on Appointment of Deputy General Manager of the Company 43

6.9 Nov 18, 2021: CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results 44

6.10 Oct 18, 2021: Straumann Group 2021 third-quarter financial results webcast invitation 46

6.11 Aug 19, 2021: CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results 46

6.12 Jul 29, 2021: Invitation: Straumann Group 2021 half-year financial results webcast 48

6.13 Jul 15, 2021: Christian Ullrich joins Straumann Group’s Executive Management Board as the new Group Chief Information Officer 48

7 Appendix 50

7.1 Methodology 50

7.2 About GlobalData 52

7.3 Contact Us 53

7.4 Disclaimer 53

Table

Tissue Regenerative Materials – Pipeline Products by Stage of Development 9

Tissue Regenerative Materials – Pipeline Products by Territory 10

Tissue Regenerative Materials – Pipeline Products by Regulatory Path 11

Tissue Regenerative Materials – Pipeline Products by Estimated Approval Date 12

Tissue Regenerative Materials – Ongoing Clinical Trials 13

Tissue Regenerative Materials Companies – Pipeline Products by Stage of Development 14

Tissue Regenerative Materials – Pipeline Products by Stage of Development 15

Advanced Biotech Products Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 16

Healiguide – Product Status 16

Healiguide – Product Description 16

Osseograft – Product Status 17

Osseograft – Product Description 17

Osseomold – Product Status 17

Osseomold – Product Description 18

Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 19

Xenograft Implant – Dental – Product Status 19

Xenograft Implant – Dental – Product Description 19

credentis AG Pipeline Products & Ongoing Clinical Trials Overview 20

CUROLOX Perio – Product Status 20

CUROLOX Perio – Product Description 20

Histocell SL Pipeline Products & Ongoing Clinical Trials Overview 21

HR018-Neofibrin – Product Status 21

HR018-Neofibrin – Product Description 21

Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 22

Electrospun Scaffold – Product Status 22

Electrospun Scaffold – Product Description 22

Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 23

MaxiGuide – Product Status 23

MaxiGuide – Product Description 23

Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 24

MD08 – Product Status 24

MD08 – Product Description 24

Nobel Biocare Services AG Pipeline Products & Ongoing Clinical Trials Overview 25

Bone Inductive Implant – Product Status 25

Bone Inductive Implant – Product Description 25

Novatissue SAS Pipeline Products & Ongoing Clinical Trials Overview 26

OrthoNovaOss – Product Status 26

OrthoNovaOss – Product Description 26

Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview 27

Striate+ – Product Status 27

Striate+ – Product Description 27

Orthorebirth Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

GCT-101 – Product Status 28

GCT-101 – Product Description 28

Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview 29

Inorganic Dental Cement – Product Status 29

Inorganic Dental Cement – Product Description 29

Straumann Holding AG Pipeline Products & Ongoing Clinical Trials Overview 30

Soft Tissue Control Implant – Product Status 30

Soft Tissue Control Implant – Product Description 30

SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

DentaColl – Product Status 31

DentaColl – Product Description 31

SweetBio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

SweetBio GTR (Guided Tissue Regeneration) Membrane – Product Status 32

SweetBio GTR (Guided Tissue Regeneration) Membrane – Product Description 32

Tetratherix Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

Tetramax – Product Status 33

Tetramax – Product Description 33

Tetratherix Pty Ltd – Ongoing Clinical Trials Overview 34

Tetramax – PET-B: Post Extraction Use of TetraMax Part B (TMB).. A Comparator Controlled Clinical Investigation Comparing the Bone Healing Capability of the Investigational Product “TetraMax Plus BioOss” and the Gold Standard Standard of Care Comparator “BioOssCollagen” (BioOssCol), for Adults Who Have Been Treatment Planned for Tooth Extraction/s and Implant Placement at the Same Extraction Site/s 35

Tigran Technologies AB Pipeline Products & Ongoing Clinical Trials Overview 36

Tigran Porous Titanium Granules – Alveolar Fillings – Product Status 36

Tigran Porous Titanium Granules – Alveolar Fillings – Product Description 36

Glossary 52

Figures

Tissue Regenerative Materials – Pipeline Products by Stage of Development 9

Tissue Regenerative Materials – Pipeline Products by Territory 10

Tissue Regenerative Materials – Pipeline Products by Regulatory Path 11

Tissue Regenerative Materials – Pipeline Products by Estimated Approval Date 12

Tissue Regenerative Materials – Ongoing Clinical Trials 13

Frequently asked questions

Tissue Regenerative Materials Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Tissue Regenerative Materials Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Tissue Regenerative Materials Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update in real time.

  • Access a live Tissue Regenerative Materials Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.